Full text is available at the source.
Clinical review of the efficacy and safety of oral semaglutide in patients with type 2 diabetes considered for injectable GLP-1 receptor agonist therapy or currently on insulin therapy
Effectiveness and safety of oral semaglutide for people with type 2 diabetes starting injectable treatment or already using insulin
AI simplified
Abstract
Oral semaglutide 14 mg provided similar reductions in glycated hemoglobin (HbA1c) compared to liraglutide after 26 weeks and significantly greater reductions at 52 weeks.
- Oral semaglutide was associated with significant weight loss compared to liraglutide after both 26 and 52 weeks.
- Patients receiving oral semaglutide 7 or 14 mg along with insulin experienced significant reductions in HbA1c and body weight at both 26 and 52 weeks compared to placebo.
- Adding oral semaglutide to insulin facilitated a decrease in total daily insulin dosage.
- The incidence of severe or blood glucose-confirmed symptomatic hypoglycemia was low when oral semaglutide was added to oral glucose-lowering therapies and did not increase when added to insulin.
- Gastrointestinal side effects were the most common adverse events associated with oral semaglutide, occurring primarily during dose escalation.
AI simplified